David Bar-Or, chief scientific officer of Ampio Pharmaceuticals (NYSE MKT: [[ticker:AMPE]]) will retire, effective Sept. 30. The Englewood, CO, company says Bar-Or will keep his positions on the board of directors and scientific advisory board. Ampio is preparing to file for FDA approval of aspartyl-alanyl diketopiperazine (Ampion), a treatment for osteoarthritis.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
